# Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

> **NCT03159702** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 43 (actual)

## Conditions studied

- Hematological Malignancy
- Multiple Myeloma

## Interventions

- **DRUG:** Evomela
- **DRUG:** Fludarabine
- **RADIATION:** Total Body Irradiation
- **OTHER:** Haploidentical Hematopoietic Cell Transplantation

## Key facts

- **NCT ID:** NCT03159702
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2024-11-12
- **Final completion:** 2025-12-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03159702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03159702, "Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03159702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*